Key result
ACEIs or β-blockers significantly reduced the risk of cardiotoxicity (HR 0.77; 95% CI 0.62-0.95) and all-cause mortality in older women with breast cancer receiving trastuzumab or anthracyclines.
Why the study?
Do angiotensin-converting enzyme inhibitors or β-blockers reduce cardiotoxicity and all-cause mortality in older women with breast cancer receiving trastuzumab or anthracyclines?
Population
6,542 women newly diagnosed with breast cancer from 2001 to 2009 undergoing trastuzumab and/or anthracycline…
Comparison
Angiotensin-converting enzyme inhibitors or… vs Nonexposed group (never prescribed ACEIs/BBs).
Design
Cohort
Authors
Loading...
Supports potential cardioprotection with ACEIs or β-blockers; leaves open need for randomized confirmation before practice change.
Cohort (n=6,542)
Do angiotensin-converting enzyme inhibitors or β-blockers reduce cardiotoxicity and all-cause mortality in older women with breast cancer receiving trastuzumab or anthracyclines?
Effect estimate: HR 0.77 (95% CI 0.62-0.95)
In older women receiving trastuzumab or anthracyclines for breast cancer, the use of ACE inhibitors or beta-blockers is associated with a significantly reduced risk of cardiotoxicity and all-cause mortality.
Wittayanukorn et al. (2017) conducted a cohort in Breast cancer (n=6,542). Angiotensin-converting enzyme inhibitors (ACEIs) or β-blockers (BBs) vs. No ACEI/BB exposure was evaluated on Cardiotoxicity (HR 0.77, 95% CI 0.62-0.95). ACEIs or β-blockers significantly reduced the risk of cardiotoxicity (HR 0.77; 95% CI 0.62-0.95) and all-cause mortality in older women with breast cancer receiving trastuzumab or anthracyclines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: